Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Soefje, Sherry
PROSPER-FM, NCT05243511: Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management	Completed	3	275	US	Digital ACT, Digital Symptom Tracker	Swing Therapeutics, Inc.	Fibromyalgia	05/23	05/23
NCT05729373: A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder	Recruiting	2/3	434	Europe, Japan, US	SEP-363856, Placebo	Otsuka Pharmaceutical Development & Commercialization, Inc.	Generalized Anxiety Disorder	02/25	02/25
PREVAIL, NCT05472090: A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection	Completed	2	63	US	TNX-102 SL, Placebo SL Tablet	Tonix Pharmaceuticals, Inc.	Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID	07/23	07/23
CL07-ORY-2001, NCT04932291 / 2020-003469-20: Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population	Completed	2	210	Europe, US, RoW	vafidemstat, ORY-2001, Placebo	Oryzon Genomics S.A.	Borderline Personality Disorder	10/23	11/23
ENLIGHTEN, NCT05113771: A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression	Completed	2	197	Canada, US	Liafensine, Placebo	Denovo Biopharma LLC	Treatment Resistant Depression	02/24	03/24
Edwards, Al-malik
PREVAIL, NCT05472090: A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection	Completed	2	63	US	TNX-102 SL, Placebo SL Tablet	Tonix Pharmaceuticals, Inc.	Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID	07/23	07/23